Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysis
- PMID: 23500086
- DOI: 10.1016/j.ygyno.2013.02.012
Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysis
Abstract
Objective: Radiation can be delivered via four-field box (BOX-RT) or intensity modulated radiation therapy (IMRT). We sought to evaluate the cost-effectiveness (C/E) of IMRT relative to BOX-RT for the treatment of locally advanced cervical cancer.
Methods: A three-year Markov model with eight-week cycles was developed to compare IMRT to BOX-RT. A proportion (25%) received extended-field radiation therapy (EFRT) to include para-aortic nodes. The model assumed equal overall survival (OS). The model captured costs and utility estimates for BOX-RT, IMRT, and each complication. Modeled complications included acute and chronic toxicities. Baseline model assumptions were obtained by literature review and supplemented by expert opinion. Costs were based on Medicare reimbursement rates and the Agency for Healthcare Research and Quality Database. Treatment strategies were compared using an incremental cost-effectiveness ratio (ICER). One-way, probabilistic and structural sensitivity analyses were performed to account for uncertainty in assumptions. The C/E of each strategy was evaluated from the perspective of the health care system.
Results: C/E analysis revealed an ICER for IMRT of $182,777/quality adjusted life year (QALY) gained. Although this value was higher than the willingness to pay threshold of $100,000/QALY, sensitivity analysis revealed several modifications that would make IMRT a C/E option relative to BOX-RT. For patients requiring EFRT, IMRT was C/E with an ICER of $91,580/QALY.
Conclusions: Although IMRT was not C/E at the $100,000 willingness-to-pay threshold, in those requiring EFRT, IMRT was C/E relative to BOX-RT. A randomized trial comparing IMRT to BOX-RT for the treatment of locally advanced cervical cancer is warranted.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.Gynecol Oncol. 2015 Mar;136(3):521-8. doi: 10.1016/j.ygyno.2014.12.039. Epub 2015 Jan 3. Gynecol Oncol. 2015. PMID: 25562668
-
Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer.Clin Oncol (R Coll Radiol). 2012 Sep;24(7):532-8. doi: 10.1016/j.clon.2012.05.010. Epub 2012 Jun 26. Clin Oncol (R Coll Radiol). 2012. PMID: 22739256
-
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):408-15. doi: 10.1016/j.ijrobp.2006.04.049. Epub 2006 Aug 2. Int J Radiat Oncol Biol Phys. 2006. PMID: 16887291
-
Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.Appl Health Econ Health Policy. 2014 Aug;12(4):391-408. doi: 10.1007/s40258-014-0106-9. Appl Health Econ Health Policy. 2014. PMID: 25022451 Review.
-
Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12430. Epub 2016 Jan 19. Eur J Cancer Care (Engl). 2018. PMID: 26782759 Review.
Cited by
-
Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy - an Option or a Must?: A Narrative Review.Cancer Res Treat. 2024 Jan;56(1):1-17. doi: 10.4143/crt.2023.562. Epub 2023 Aug 30. Cancer Res Treat. 2024. PMID: 37654111 Free PMC article. Review.
-
Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer.Gynecol Oncol. 2023 Jun;173:81-87. doi: 10.1016/j.ygyno.2023.04.010. Epub 2023 Apr 25. Gynecol Oncol. 2023. PMID: 37105061 Free PMC article.
-
Cost-Effectiveness Analysis of Diagnostic Tests for Para-Aortic Lymph Node Detection in Locally Advanced Cervical Cancer.Clinicoecon Outcomes Res. 2021 Nov 22;13:943-955. doi: 10.2147/CEOR.S327698. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34848981 Free PMC article.
-
Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma.Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):964-973. doi: 10.1016/j.ijrobp.2020.04.019. Epub 2020 Apr 22. Int J Radiat Oncol Biol Phys. 2020. PMID: 32334034 Free PMC article. Clinical Trial.
-
A comparative dosimetric study of cervical cancer patients with para-aortic lymph node metastasis treated with volumetric modulated arc therapy vs. 9-field intensity-modulated radiation therapy.Ann Transl Med. 2019 Nov;7(22):675. doi: 10.21037/atm.2019.10.53. Ann Transl Med. 2019. PMID: 31930076 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
